Tag Archives: OVA2

March, 2016

  • 21 March

    Vermillion’s Ovarian Cancer Test Overa Receives FDA Clearance

    AUSTIN, Texas, March 21, 2016 /PRNewswire/ — Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today the receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for the successor to Vermillion’s OVA1® test for determining ovarian cancer risk in conjunction with …